Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

X4 Pharmaceuticals Inc (XFOR)

X4 Pharmaceuticals Inc (XFOR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 166,595
  • Shares Outstanding, K 167,938
  • Annual Sales, $ 0 K
  • Annual Income, $ -101,170 K
  • 60-Month Beta 0.40
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade XFOR with:

Options Overview Details

View History
  • Implied Volatility 94.51% ( -16.53%)
  • Historical Volatility 59.41%
  • IV Percentile 21%
  • IV Rank 23.17%
  • IV High 294.03% on 09/01/23
  • IV Low 34.35% on 09/13/23
  • Put/Call Vol Ratio 0.00
  • Today's Volume 225
  • Volume Avg (30-Day) 541
  • Put/Call OI Ratio 0.12
  • Today's Open Interest 29,074
  • Open Int (30-Day) 26,704

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/24
See More
  • Average Estimate -0.04
  • Number of Estimates 6
  • High Estimate 0.34
  • Low Estimate -0.24
  • Prior Year -0.33
  • Growth Rate Est. (year over year) +87.88%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.8600 +12.23%
on 05/21/24
1.1300 -14.58%
on 06/13/24
+0.0368 (+3.96%)
since 05/17/24
3-Month
0.8600 +12.23%
on 05/21/24
1.6000 -39.68%
on 04/03/24
+0.0419 (+4.54%)
since 03/18/24
52-Week
0.5723 +68.65%
on 12/12/23
2.1300 -54.69%
on 06/20/23
-1.1948 (-55.31%)
since 06/16/23

Most Recent Stories

More News
3 Microcap Stocks With Big Breakout Potential

Analysts see substantial potential for price appreciation in these three microcap stocks from their current levels.

BTBT : 2.80 (-2.10%)
^BTCUSD : 64,639.59 (-2.91%)
^ETHUSD : 3,399.483 (-4.08%)
RGTI : 0.9901 (-4.80%)
XFOR : 0.9600 (-3.23%)
Pharming to nominate industry leader Dr. Richard Peters as new Chairman of the Board

/PRNewswire/ -- Pharming Group N.V. ("Pharming" or "the Company") (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces today that the Board of Directors has...

PHAR : 8.45 (+2.74%)
KA : 0.4952 (-8.30%)
APRE : 4.22 (+0.48%)
XFOR : 0.9600 (-3.23%)
What Makes X4 Pharmaceuticals (XFOR) a New Buy Stock

X4 Pharmaceuticals (XFOR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

XFOR : 0.9600 (-3.23%)
Scorpion Therapeutics Announces Formation of World-Class Clinical Scientific Advisory Board

Scorpion Therapeutics, Inc. (“Scorpion Therapeutics”), a pioneering oncology company redefining the frontier of precision medicine through its Precision Oncology 2.0 strategy, today announced the formation...

XFOR : 0.9600 (-3.23%)
X4 Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Highlights notable upcoming milestones including data from Phase 1b trial in chronic neutropenia, expected in late September, and results from global,...

XFOR : 0.9600 (-3.23%)
X4 Pharmaceuticals to Announce Second Quarter 2022 Financial Results and Host a Conference Call and Webcast on August 4, 2022

BOSTON, July 26, 2022 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel CXCR4-targeted...

XFOR : 0.9600 (-3.23%)
X4 Pharmaceuticals Announces Strategic Prioritization of Programs and Resources Extending Cash Runway Through Expected Key Clinical and Regulatory Milestones

Company now focused on advancing lead clinical candidate mavorixafor in chronic neutropenic disorders, including WHIM syndrome Important mavorixafor...

XFOR : 0.9600 (-3.23%)
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, July 01, 2022 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel CXCR4-targeted...

XFOR : 0.9600 (-3.23%)
X4 Pharmaceuticals Announces $55 Million Private Placement Financing and Debt Facility Amendment Extending Interest-Only Period by up to 12 Months

BOSTON, June 30, 2022 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel CXCR4-targeted...

XFOR : 0.9600 (-3.23%)
X4 Pharmaceuticals to Present Research Data at the 2022 European Hematology Association (EHA) Congress Supporting Mechanism and Market Potential for Mavorixafor

BOSTON, May 16, 2022 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel CXCR4-targeted small...

XFOR : 0.9600 (-3.23%)

Business Summary

X4 Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of novel therapeutics for the treatment of rare diseases. The company's product candidates include X4P-001, X4P-002 and X4P-003 which are in clinical stage. X4 Pharmaceuticals...

See More

Key Turning Points

3rd Resistance Point 1.0936
2nd Resistance Point 1.0618
1st Resistance Point 1.0269
Last Price 0.9600
1st Support Level 0.9602
2nd Support Level 0.9284
3rd Support Level 0.8935

See More

52-Week High 2.1300
Fibonacci 61.8% 1.5350
Fibonacci 50% 1.3512
Fibonacci 38.2% 1.1673
Last Price 0.9600
52-Week Low 0.5723

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar